H.B. Fuller: Sticky Business, Stickier Balance Sheet

# H.B. Fuller: Sticky Business, Stickier Balance Sheet

There's a certain irony in writing about an adhesives company that can't quite get its own stock to stick to a trend. H.B. Fuller (FUL) just posted a genuinely good quarter, raised prices globally, and made an aggressive play for a British medical supplier — and the stock is doing what it's done for the better part of a year: absolutely nothing, bouncing between $48 and $68 like it's stuck to a pendulum instead of a pipeline.

Let's start with what's actually working, because there's more here than the ticker suggests.

The Numbers Don't Lie — Q2 Was Clean

Revenue hit $950 million in Q2, up 5.8% year-over-year. Adjusted gross margin expanded 200 basis points to 34.2%. Adjusted EBITDA jumped 9% to $181 million. Adjusted EPS climbed 19% to $1.41. Operating cash flow hit a record $121 million. This is not a company limping through a rough patch — this is a company executing a pricing strategy and actually collecting on it.

And they're not done squeezing. The global price adjustment effective April 1 — a minimum 10% increase across every product line — is a direct shot at petrochemical cost inflation and supply-chain jitters out of the Middle East. Say what you want about pricing power, but when you can raise prices double digits across a 20,000-product portfolio and still grow volumes in two of three segments, that's not luck. That's a company with genuine pricing leverage in a fragmented, sticky-by-nature (pun intended) industry where switching adhesive suppliers mid-production-line is nobody's idea of a good Tuesday.

The AMS Deal Is the Real Story Here

Forget the quarter for a second — the more interesting question is what H.B. Fuller wants to become. The cash offer for Advanced Medical Solutions Group is a straight-up bet that the company's future is less about caulking building envelopes and more about medical-grade adhesives. The deal is expected to expand the total addressable market by $15 billion, to $95 billion, and tack on roughly $300 million in annual revenue with a mix shift toward higher-margin healthcare applications.

That's the kind of portfolio reshaping that, if it works, re-rates the stock from "industrial materials company with a decent yield" to "specialty chemicals company with a medical growth story." Fitch didn't blink either, affirming the BB issuer rating with a stable outlook post-announcement — which matters given the leverage conversation below.

Of course, not everyone was thrilled. Activist investor Ancora Holdings came in hot in late May, pushing management to abandon the AMS chase entirely in favor of a strategic review. The stock dropped over 5% on the news before management held the line — and shares actually rallied 4.8% once it became clear the deal was staying alive. Make of that what you will, but the market's verdict was pretty clear: it wanted the deal, not the retreat.

Now the Part Nobody Wants to Talk About

Here's my problem with the bull case as currently constructed: debt-to-equity sitting north of 106 and ROIC languishing at 4.47% are not rounding errors. This is a company generating solid cash flow and expanding margins while still carrying a balance sheet that limits how aggressive it can really get. Management itself seems to know this — note the pivot in Q2 toward debt reduction and buybacks, effectively pausing further acquisitions to get the house in order. That's a tacit admission that the balance sheet needs attention before FUL goes shopping for its next AMS.

Segment-level cracks are worth watching too — mid-single-digit declines in parts of engineering adhesives and softness in flexible packaging and automotive aren't nothing. This isn't a company firing on all cylinders; it's firing on most of them, with a couple misfiring quietly in the back.

Where This Leaves You

The chart is annoying — sideways, with the 20-day and 50-day moving averages both trending down even as fundamentals improve, which is exactly the kind of divergence that makes technical traders and fundamental investors argue at parties. Analyst targets in the $73–78 range against a stock trading in the mid-$50s suggest the market hasn't fully priced the pricing power, the margin expansion, or the AMS optionality.

My take: this is a hold with a raised eyebrow toward accumulation, not a chase. Watch $58.74 as the line in the sand — a clean break above on continued margin expansion and AMS progress, and the re-rating case gets real. Below $51.68, the debt story starts to matter more than the medical-adhesives dream. Either way, Q3 earnings on September 30 will tell you which narrative wins. Until then, FUL is a good business wearing a mediocre stock's clothes — and the difference between the two usually closes eventually. The only question is which direction it breaks.